Osaic Holdings
BTAI icon

Osaic Holdings’s BioXcel Therapeutics BTAI Stock Holding History

Osaic Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7K Buy
16,214
+465
+3% +$766 ﹤0.01% 5799
2025
Q4 		$25.2K Buy
15,749
+666
+4% +$1.37K ﹤0.01% 5715
2025
Q3 		$61.1K Buy
15,083
+10,030
+198% +$31.6K ﹤0.01% 5185
2025
Q2 		$9.14K Buy
5,053
+3,169
+168% +$5.25K ﹤0.01% 6213
2025
Q1 		$3.82K Buy
1,884
+954
+103% +$3.56K ﹤0.01% 6313
2024
Q4 		$5.5K Buy
930
+399
+75% +$3.33K ﹤0.01% 6140
2024
Q3 		$5.18K Buy
531
+242
+84% +$3.25K ﹤0.01% 6174
2024
Q2 		$5.93K Buy
289
+218
+307% +$7.3K ﹤0.01% 6087
2024
Q1 		$3.19K Buy
71
+44
+163% +$2.1K ﹤0.01% 6292
2023
Q4 		$1.27K Buy
27
+8
+42% +$445 ﹤0.01% 6669
2023
Q3 		$759 Sell
19
-117
-86% -$11.8K ﹤0.01% 6904
2023
Q2 		$14.4K Buy
136
+25
+23% +$8.32K ﹤0.01% 5763
2023
Q1 		$33.1K Sell
111
-52
-32% -$22.2K ﹤0.01% 5248
2022
Q4 		$56K Sell
163
-15
-8% -$3.63K ﹤0.01% 4844
2022
Q3 		$34K Sell
178
-41
-19% -$9.52K ﹤0.01% 5194
2022
Q2 		$47K Sell
219
-24
-10% -$5.05K ﹤0.01% 5001
2022
Q1 		$94K Buy
243
+28
+13% +$8.12K ﹤0.01% 4638
2021
Q4 		$70K Sell
215
-743
-78% -$319K ﹤0.01% 4882
2021
Q3 		$465K Buy
958
+84
+10% +$36.9K ﹤0.01% 3104
2021
Q2 		$406K Buy
874
+255
+41% +$139K ﹤0.01% 3234
2021
Q1 		$428K Buy
619
+340
+122% +$274K ﹤0.01% 3038
2020
Q4 		$206K Buy
279
+63
+29% +$49.1K ﹤0.01% 3458
2020
Q3 		$152K Buy
216
+124
+135% +$93.1K ﹤0.01% 3490
2020
Q2 		$78K Sell
92
-22
-19% -$14.3K ﹤0.01% 3869
2020
Q1 		$39K Buy
+114
New +$41K ﹤0.01% 4158

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Osaic Holdings's BTAI Position: Q1 2026 in Review

Osaic Holdings increased its BioXcel Therapeutics (BTAI) stake by 3% in Q1 2026, buying an estimated $766 and bringing the position to 16,214 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5799.

Osaic Holdings first reported a position in BTAI in Q1 2020 and has held it in 25 quarters since. The position peaked at $465K in Q3 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Osaic Holdings held 16,214 shares of BioXcel Therapeutics worth $21.7K as of Q1 2026.
  • Osaic Holdings bought 465 BioXcel Therapeutics shares in Q1 2026, an estimated $766.
  • BioXcel Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5799 holding.
  • Osaic Holdings first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Osaic Holdings's BioXcel Therapeutics position peaked at $465K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.